Vidofludimus Calcium Safely Reduced RRMS Brain Lesions Vidofludimus calcium, also called IMU-838, is an oral therapy designed to reduce the activity of B- and T-cells. These are immune cells believed to be responsible for the inflammation that results in MS damage. In this small study, active lesions — including…
Dysport
Dysport (abobotulinumtoxinA), a form of purified botulinum toxin, has received a positive opinion in Europe for managing urinary incontinence in adults with neurogenic detrusor overactivity (NDO), or overactive bladder. The opinion is specifically for those who experience bladder issues due to multiple sclerosis (MS) or spinal cord…
I’ve just received four intramuscular Botox injections in my right arm to relieve the muscle spasticity that comes with multiple sclerosis. (OK, it wasn’t actually Botox, but Dysport, or abobotulinumtoxinA, another medication derived from the botulinum toxin to block muscle contractions.) And “my right arm is going…
MS News That Caught My Eye This Week: Brain Scans, Spasticity, Tecfidera Study and Cigarettes
In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week. **** Harvard Study Finds No Link Between Clinical Exams and MRIs in Some MS Patients I’m really not surprised…
The U.S. Food and Drug Administration (FDA) has expanded approval of Dysport (abobotulinumtoxinA) for treatment of spasticity in adults, a condition that affects many people in the United States, including multiple sclerosis patients. The decision was based on Dysport’s supplemental Biologics License Application (sBLA)…
Ipsen Biopharmaceuticals, Inc announced that the United States Food and Drug Administration (FDA) has agreed to review the supplemental Biologics License Application (sBLA) for Dysport® (abobotulinumtoxinA) to treat upper limb spasticity, a condition that affects many people in the United States, including multiple sclerosis (MS)…